{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:51:29Z","timestamp":1790869889607,"version":"4.1.0"},"reference-count":22,"publisher":"e-Century Publishing Corporation","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/yhuw1294","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T03:35:57Z","timestamp":1727667357000},"page":"4506-4513","source":"Crossref","is-referenced-by-count":4,"title":["Gemcitabine\/Cisplatin versus docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy in locally advanced nasopharyngeal carcinoma"],"prefix":"10.62347","volume":"14","author":[{"given":"Fatma","family":"Gharib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y and Ma J. Nasopharyngeal carcinoma. Lancet 2019; 394: 64-80.","journal-title":"Lancet"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","article-title":"Nasopharyngeal carcinoma","volume":"387","author":"Chua","year":"2016","unstructured":"Chua MLK, Wee JTS, Hui EP and Chan ATC. Nasopharyngeal carcinoma. Lancet 2016; 387: 1012-24.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(†)","volume":"32","author":"Bossi","year":"2021","unstructured":"Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J, Smeele L, van Herpen C, Castro A and Machiels JP; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org; EURACAN. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). Ann Oncol 2021; 32: 452-65.","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jama.2022.13997","article-title":"Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial","volume":"328","author":"Tang","year":"2022","unstructured":"Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y and Ma J. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA 2022; 328: 728-36.","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2018.10.020","article-title":"Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma","volume":"110","author":"XY","year":"2019","unstructured":"Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, Liu LT, Xie HJ, Tang QN, Liang YJ, Wen YF, Guo L, Mo HY, Chen MY, Sun Y, Ma J, Tang LQ and Mai HQ. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer 2019; 110: 24-31.","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial","volume":"75","author":"Cao","year":"2017","unstructured":"Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X and Hong MH. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer 2017; 75: 14-23.","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang","year":"2019","unstructured":"Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH and Chen MY. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 2019; 119: 87-96.","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/annonc\/mdy249","article-title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study","volume":"29","author":"Hong","year":"2018","unstructured":"Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC and Liu TW. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol 2018; 29: 1972-9.","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y and Ma J. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol 2021; 39: 840-59.","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y and Ma J. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019; 381: 1124-35.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial","volume":"40","author":"Zhang","year":"2022","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Xie FY, Sun Y, Ma J and Tang LL. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol 2022; 40: 2420-5.","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","article-title":"International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma","volume":"126","author":"AW","year":"2018","unstructured":"Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O’Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Soong YL, Tao Y, Yom SS and Wee JT. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother Oncol 2018; 126: 25-36.","journal-title":"Radiother Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC and Chan AT. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242-9.","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ and Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17: 1509-20.","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis","volume":"24","author":"Petit","year":"2023","unstructured":"Petit C, Lee A, Ma J, Lacas B, Ng WT, Chan ATC, Hong RL, Chen MY, Chen L, Li WF, Huang PY, Tan T, Ngan RKC, Zhu G, Mai HQ, Hui EP, Fountzilas G, Zhang L, Carmel A, Kwong DLW, Moon J, Bourhis J, Auperin A, Pignon JP and Blanchard P; MAC-NPC Collaborative Group. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol 2023; 24: 611-23.","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2018.02.011","article-title":"Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: a big-data intelligence platform-based analysis","volume":"79","author":"Peng","year":"2018","unstructured":"Peng H, Tang LL, Chen BB, Chen L, Li WF, Mao YP, Liu X, Zhang Y, Liu LZ, Tian L, Guo Y, Sun Y and Ma J. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: a big-data intelligence platform-based analysis. Oral Oncol 2018; 79: 40-6.","journal-title":"Oral Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","article-title":"Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials","volume":"47","author":"AW","year":"2011","unstructured":"Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, Siu L, Tan T, Chan LK, Ng WT, Leung TW, Fu YT, Au GK, Zhao C, O’Sullivan B, Tan EH and Lau WH. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer 2011; 47: 656-66.","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/hed.20421","article-title":"Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma","volume":"28","author":"Yau","year":"2006","unstructured":"Yau TK, Lee AW, Wong DH, Yeung RM, Chan EW, Ng WT, Tong M and Soong IS. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head Neck 2006; 28: 880-7.","journal-title":"Head Neck"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.7150\/jca.16732","article-title":"Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy","volume":"8","author":"Peng","year":"2017","unstructured":"Peng H, Chen L, Zhang J, Li WF, Mao YP, Zhang Y, Liu LZ, Tian L, Lin AH, Sun Y and Ma J. Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy. J Cancer 2017; 8: 371-7.","journal-title":"J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","article-title":"The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma","volume":"93","author":"Liu","year":"2015","unstructured":"Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, Mo HY, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J and Mai HQ. The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2015; 93: 862-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.oraloncology.2019.08.001","article-title":"Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma","volume":"97","author":"Zhu","year":"2019","unstructured":"Zhu J, Duan B, Shi H, Li Y, Ai P, Tian J and Chen N. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol 2019; 97: 37-43.","journal-title":"Oral Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"15581","DOI":"10.1038\/s41598-018-33614-5","article-title":"Assessment of concurrent chemoradiotherapy plus induction chemotherapy in advanced nasopharyngeal carcinoma: cisplatin, fluorouracil, and docetaxel versus gemcitabine and cisplatin","volume":"8","author":"Zeng","year":"2018","unstructured":"Zeng Z, Yan RN, Tu L, Wang YY, Chen PR, Luo F and Liu L. Assessment of concurrent chemoradiotherapy plus induction chemotherapy in advanced nasopharyngeal carcinoma: cisplatin, fluorouracil, and docetaxel versus gemcitabine and cisplatin. Sci Rep 2018; 8: 15581.","journal-title":"Sci Rep"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/9\/ajcr0158971.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:56:52Z","timestamp":1766023012000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/9\/ajcr0158971.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/yhuw1294","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}